5 recruiting, 1 completed, 1 terminated. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 5, Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Edesa Biotech Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo Placebo IV, EB06 - Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | Edesa Biotech Inc. | 80 | 2026-09-01 | 2026-10-27 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab Cohort C: bevacizumab, Cohort C: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-10-28 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab Cohort A: vilobelimab, Cohort A: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-21 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 600 | 2025-06-10 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart Cohort B: paridiprubart, Cohort B: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-10 | 2026-07-31 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19 SOC plus 15mg/kg EB05 IV, SOC plus Placebo IV - COVID-19, ARDS | Phase 2 / Phase 3 | Terminated | Edesa Biotech Inc. | 278 | 2020-11-25 | 2026-10-28 |
| Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0% - Allergic Contact Dermatitis | Phase 2 | Completed | Edesa Biotech Inc. | 211 | 2019-10-15 | 2024-11-14 |
Acute Lung Injury (4) · Respiratory Distress Syndrome (4) · COVID-19 (1) · Dermatitis, Allergic Contact (1)
United States (6) · Canada (3)